tiprankstipranks
Bavarian Nordic A/S (BVNRY)
OTHER OTC:BVNRY
US Market

Bavarian Nordic (BVNRY) Stock Price & Analysis

87 Followers

BVNRY Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$5.99 - $9.59
Previous Close$8.6
Volume15.57K
Average Volume (3M)4.27K
Market Cap
$2.01B
Enterprise Value$1.85B
Total Cash (Recent Filing)kr2.85B
Total Debt (Recent Filing)kr1.76B
Price to Earnings (P/E)13.9
Beta1.45
Aug 22, 2024
EPS EstimateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.62
Shares Outstanding233,180,193
10 Day Avg. Volume5,172
30 Day Avg. Volume4,274
Standard Deviation0.17
R-Squared0.25
Alpha-0.00179
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

0.00%0.02%0.01%99.97%
0.00%
Insiders
0.01% Other Institutional Investors
99.97% Public Companies and
Individual Investors

BVNRY FAQ

What was Bavarian Nordic A/S’s price range in the past 12 months?
Bavarian Nordic A/S lowest stock price was $5.99 and its highest was $9.59 in the past 12 months.
    What is Bavarian Nordic A/S’s market cap?
    Currently, no data Available
    When is Bavarian Nordic A/S’s upcoming earnings report date?
    Bavarian Nordic A/S’s upcoming earnings report date is Aug 22, 2024 which is in 36 days.
      How were Bavarian Nordic A/S’s earnings last quarter?
      Bavarian Nordic A/S released its earnings results on May 08, 2024. The company reported -$0.071 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.071.
        Is Bavarian Nordic A/S overvalued?
        According to Wall Street analysts Bavarian Nordic A/S’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Bavarian Nordic A/S pay dividends?
          Bavarian Nordic A/S pays a Notavailable dividend of $0.42 which represents an annual dividend yield of N/A. See more information on Bavarian Nordic A/S dividends here
            What is Bavarian Nordic A/S’s EPS estimate?
            Bavarian Nordic A/S’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Bavarian Nordic A/S have?
            Bavarian Nordic A/S has 234,351,940 shares outstanding.
              What happened to Bavarian Nordic A/S’s price movement after its last earnings report?
              Bavarian Nordic A/S reported an EPS of -$0.071 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.128%.
                Which hedge fund is a major shareholder of Bavarian Nordic A/S?
                Currently, no hedge funds are holding shares in BVNRY
                ---

                Bavarian Nordic Stock Smart Score

                10
                Unlock Smart Score
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Technicals

                SMA
                Positive
                20 days / 200 days
                Momentum
                -10.58%
                12-Months-Change

                Fundamentals

                Return on Equity
                10.15%
                Trailing 12-Months
                Asset Growth
                2.59%
                Trailing 12-Months

                Company Description

                Bavarian Nordic A/S

                Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. It specializes in cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian and prostate cancer. Its products include IMVAMUNE for Ebola, HPV, HBV, and HIV diseases. The company was founded in 1994 and is headquartered in Kvistgaard, Denmark.
                ---

                BVNRY Company Deck

                ---

                BVNRY Earnings Call

                Q1 2024
                0:00 / 0:00
                ---
                Similar Stocks
                Company
                Price & Change
                Follow
                Takeda Pharmaceutical Company
                BioNTech SE
                Moderna
                AstraZeneca
                Popular Stocks
                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis